A brief post on some interviews I gave recently on esketamine for treatment-resistant depression and depression in women who have problems getting pregnant.
The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
The problem of withdrawal syndromes and emotional blunting occurring with prolonged antidepressant treatment is constantly underestimated by clinicians.
An article on the front page of the New York Times on April 7, 2018, has fueled the debate over antidepressants again.
Andrea Cipriani from the University of Oxford and colleagues have recently published the largest and most comprehensive meta-analysis of the efficacy of antidepressants in the Lancet. The paper is worth dealing with more intensively.